Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.38 |
| ▸ | CHKA | P35790 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.36 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL951610 | 0.83 | PSEN1 (0.40) | HSD11B1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL22725318 | 0.81 | MEN1 (0.40) | HSD11B1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL29188773 | 0.81 | HSD11B1 (0.39) | HSD11B1CA2CA12CA1CA9 | |
| SCHEMBL22967561 | 0.80 | HSD11B1 (0.43) | HSD11B1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL22720076 | 0.79 | GAA (0.47) | — | |
| SCHEMBL15106195 | 0.79 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL31085608 | 0.79 | PSEN1 (0.40) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL18703623 | 0.77 | HSD11B1 (0.49) | HSD11B1CA2CA12CA1CA9 | |
| Hydrochloric Acid SCHEMBL18689553 | 0.76 | HSD11B1 (0.47) | HSD11B1CA2CA12CA1CA9 | |
| SCHEMBL31573268 | 0.75 | PSEN1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117229215-A | Biaryl compound, pharmaceutical composition containing biaryl compound, preparation method and application of biaryl compound | 四川科伦博泰生物医药股份有限公司 | 2023-12-15 | — | — | CN | disclosed |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
| CN-114096525-B | Biaryl compound, pharmaceutical composition containing biaryl compound, preparation method and application of biaryl compound | 四川科伦博泰生物医药股份有限公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-114096525-A | Biaryl compounds, pharmaceutical compositions containing them, processes for their preparation and their use | 四川科伦博泰生物医药股份有限公司 | 2022-02-25 | — | — | CN | disclosed |
| WO-2021047407-A1 | BIARYL COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2021-03-18 | — | — | WO | disclosed |
| WO-2021047407-A1 | BIARYL COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2021-03-18 | — | — | WO | disclosed |
| US-20210040089-A1 | KRAS MUTANT PROTEIN INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. | 2021-02-11 | — | — | US | disclosed |
| WO-2021023247-A1 | KRAS MUTANT PROTEIN INHIBITOR | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2021-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040089-A1 | KRAS MUTANT PROTEIN INHIBITORS | KRAS, NRAS, APC | HSD11B1 3819/4885CA2 3435/4885CA12 4316/4885 |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | KRAS, NRAS, HRAS | HSD11B1 155/4885CA2 3488/4885CA12 2751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.